Eli Lilly and Nvidia launched a collaboration focused on applying advanced artificial intelligence (AI) to drug development. The initiative is backed by a joint investment of up to $1 billion over five years.
The partnership will establish a new lab in the San Francisco Bay Area. This facility combines Lilly’s expertise in medicine and biology with Nvidia’s leadership in AI and accelerated computing.
The primary goal is to shorten the path from early research to viable medicines. The project achieves this by building powerful AI models and generating large-scale biological data.
The initiative expands on Lilly’s previously announced AI supercomputer. It will utilize Nvidia’s BioNeMo platform and next-generation architectures to enhance the overall drug discovery process.